Examining the link between residual tumor and outcomes after targeted therapy in lung cancer
Association Between Residual Viable Tumor and Prognosis After Neoadjuvant Targeted Therapy in EGFR-Mutated Non-small Cell Lung Cancer
This study looks at how leftover tumor tissue after treatment affects survival in patients with a specific type of lung cancer who have received targeted therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06771960 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between residual viable tumor (RVT) and survival outcomes in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have undergone neoadjuvant targeted therapy. By analyzing data from patients treated at Guangdong Provincial People's Hospital, the study aims to clarify the prognostic significance of RVT in predicting disease-free and event-free survival. The findings could enhance understanding of RVT as a biomarker, potentially guiding postoperative management and risk stratification for patients. This retrospective analysis focuses on the importance of pathological evaluation of RVT to improve treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-80 with pathologically diagnosed EGFR-mutated NSCLC who have received neoadjuvant targeted therapy and are scheduled for definitive surgery.
Not a fit: Patients with a history of prior chemotherapy, immunotherapy, or radiotherapy, or those with other malignancies or lung surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the prognostic value of RVT, helping to optimize treatment plans for lung cancer patients.
How similar studies have performed: While the prognostic role of RVT in lung cancer has been explored, this specific association in the context of neoadjuvant targeted therapy for EGFR-mutated NSCLC is novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-80 years old; * Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC); * Treated with neoadjuvant targeted therapy; * Undergoing definitive surgery. Exclusion Criteria: * A history of prior chemotherapy, immunotherapy, or radiotherapy. * A history of malignancy or lung surgery; * Missing key data.
Where this trial is running
Guangzhou, Guangdong
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Guibin Qiao — Guangdong Provincial People's Hospital
- Study coordinator: Guibin Qiao
- Email: guibinqiao@126.com
- Phone: +86-13602749153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.